NCT00830219View on ClinicalTrials.gov

The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

November 30, 2004

Study Completion Date

November 30, 2004

Conditions
Healthy
Interventions
DRUG

Ropinirole HCl 0.25 mg Tablets

1 x 0.25 mg, single dose fed

DRUG

Requip® 0.25 mg Tablets

1 x 0.25 mg, single dose fed

Trial Locations (1)

77042

Novum Pharmaceutical Research Services, Houston

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00830219 - The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions | Biotech Hunter | Biotech Hunter